13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

58 trials found

diseases per page:

Showing 1 to 10 of 58 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2016-002820-10-DE (EUCTR)	26/06/2017	08/11/2016	Efficacy and Safety of Daclizumab in Participants with RRMS Switching from Natalizumab	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, ...	Remitting-Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063399;T ...	Trade Name: Zinbryta Product Name: Daclizumab Product Code: BIIB019 INN or Proposed INN: Daclizumab Othe ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	United States;Canada;Germany;Italy;United Kingdom
2	NCT02881567 (ClinicalTrials.gov)	April 18, 2017	24/8/2016	Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, ...	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: Daclizumab	Biogen	AbbVie	Terminated	18 Years	55 Years	All	41	Phase 3	United States;Canada;Germany;Italy;Puerto Rico;France;United Kingdom
3	EUCTR2016-002820-10-IT (EUCTR)	31/03/2017	13/01/2021	Efficacy and Safety of Daclizumab in Participants with RRMS Switching from Natalizumab	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, ...	Remitting-Relapsing Multiple Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Trade Name: Zinbryta Product Name: Daclizumab Product Code: BIIB019 INN or Proposed INN: DACLIZUMAB Othe ...	BIOGEN IDEC RESEARCH LIMITED	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	France;United States;Canada;Denmark;Germany;United Kingdom;Italy
4	EUCTR2016-002820-10-GB (EUCTR)	13/03/2017	08/11/2016	Efficacy and Safety of Daclizumab in Participants with RRMS Switching from Natalizumab	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, ...	Remitting-Relapsing Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063399;T ...	Trade Name: Zinbryta Product Name: Zinbryta Product Code: BIIB019 INN or Proposed INN: Daclizumab Other ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 3	France;United States;Canada;Denmark;Germany;Italy;United Kingdom
5	EUCTR2012-003176-39-DK (EUCTR)	30/10/2013	25/10/2013	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 203MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, ...	Relapsing-remitting Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063399;T ...	Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab Other descriptive nam ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	1600	Phase 3	Argentina;Brazil;Poland;Romania;Georgia;Germany;Sweden;Serbia;United States;Greece;Spain;Ukraine;Ire ...
6	EUCTR2012-003176-39-IE (EUCTR)	01/08/2013	11/04/2013	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, ...	Relapsing-remitting Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063399;T ...	Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab Other descriptive nam ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	1600	Phase 3	Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India; ...
7	EUCTR2012-003176-39-GB (EUCTR)	31/07/2013	12/04/2013	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, ...	Relapsing-remitting Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063399;T ...	Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab Other descriptive nam ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	1600	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India; ...
8	EUCTR2012-003176-39-GR (EUCTR)	14/07/2013	22/05/2013	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 203MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, ...	Relapsing-remitting Multiple Sclerosis MedDRA version: 16.0;Level: PT;Classification code 10063399;T ...	Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab Other descriptive nam ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	1841	Phase 3	United States;Serbia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Italy;Switzerland;India; ...
9	EUCTR2012-003176-39-FI (EUCTR)	11/06/2013	14/05/2013	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 203MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, ...	Relapsing-remitting Multiple Sclerosis MedDRA version: 14.1;Level: PT;Classification code 10063399;T ...	Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab Other descriptive nam ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	1841		United States;Serbia;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Italy;Switzerland;India; ...
10	EUCTR2012-003176-39-DE (EUCTR)	31/05/2013	14/12/2012	Daclizumab HYP Extension Study for Subjects with Multiple Sclerosis Who Have Completed 205MS301	A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, ...	Relapsing-remitting Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10063399;T ...	Product Name: DACLIZUMAB HYP Product Code: BIIB019 INN or Proposed INN: Daclizumab Other descriptive nam ...	Biogen Idec Research Limited	NULL	Not Recruiting			Female: yes Male: yes	1600	Phase 3	Serbia;United States;Greece;Spain;Ukraine;Ireland;Russian Federation;Israel;Switzerland;Italy;India; ...

First Previous1 2 3 4 5 6Next Last